Stock listing
OTC:WINT Windtree Therapeutics, Inc. Stock
Follow Windtree Therapeutics, Inc. into a list and get an email when it puts out news.

- Ticker
- OTC:WINT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Windtree Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 37 decks · latest Oct 1, 2024
Valuation
balance Sep 30, 2025
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.57
Events
| Quarter | Results |
|---|---|
| Q3 2025 | Nov 19, 2025 |
| Q2 2025 | Aug 19, 2025 |
| Q1 2025 | May 13, 2025 · After close |
| Q3 2024 | Nov 26, 2024 · After close |
| Q2 2024 | Aug 19, 2024 · After close |
| Q1 2024 | May 15, 2024 · After close |
| Q4 2023 | Mar 29, 2024 · After close |
| Q3 2023 | Nov 9, 2023 · After close |
| Q2 2023 | Aug 7, 2023 · After close |
| Q1 2023 | Apr 3, 2023 · Before open |
All 19 quarters
| Quarter | Results |
|---|---|
| Q4 2022 | Mar 31, 2023 · After close |
| Q3 2022 | Nov 14, 2022 · Before open |
| Q2 2022 | Aug 11, 2022 · After close |
| Q1 2022 | May 5, 2022 · After close |
| Q4 2021 | Mar 31, 2022 · Before open |
| Q3 2021 | Nov 10, 2021 · After close |
| Q2 2021 | Aug 5, 2021 · After close |
| Q1 2021 | May 13, 2021 · Before open |
| Q4 2020 | Mar 29, 2021 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2024) | Investor deck | 38 slides | Oct 1, 2024 |
| Investor Presentation (September 2024) | Investor deck | 32 slides | Sep 13, 2024 |
| Investor Presentation (July 2024) | Investor deck | 32 slides | Jul 3, 2024 |
| Investor Presentation (November 2023) | Investor deck | 31 slides | Nov 9, 2023 |
| Investor Presentation (September 2023) | Investor deck | 31 slides | Sep 26, 2023 |
| Investor Day (June 2023) | Investor day | 42 slides | Jun 14, 2023 |
| Investor Presentation (April 2023) | Investor deck | 37 slides | Apr 3, 2023 |
| Investor Presentation (November 2022) | Investor deck | 42 slides | Nov 14, 2022 |
| Investor Presentation (August 2022) | Investor deck | 42 slides | Aug 11, 2022 |
| Investor Presentation (July 2022) | Investor deck | 42 slides | Jul 18, 2022 |
All 37 decks
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 198.0K | 1.79M | 1.49M | 2.04M | 987.0K |
| Cost of revenue | 84.0K | 82.0K | 1.06M | 869.0K | 638.0K | 12.7K | 10.6M | 17.4M | 255.0K | 929.0K |
| Gross profit | -84.0K | -82.0K | -1.06M | -869.0K | -638.0K | 185.3K | -8.77M | -15.9M | 1.79M | 58.0K |
| Research and development | 16.3M | 8.26M | 11.1M | 17.8M | 15.4M | 12.7M | 10.6M | 17.4M | 31.7M | 28.9M |
| Selling, general and administrative | 8.74M | 8.70K | 10.8M | 14.5M | 14.9M | 12.4M | 7.42M | 6.66M | 7.17M | 11.0M |
| Operating income | -25.0M | -17.5M | -41.3M | -77.3M | -30.3M | -24.9M | -16.2M | -22.5M | -38.0M | -39.8M |
| Depreciation and amortization | 84.0K | 82.0K | 533.0K | 192.0K | 168.0K | 195.0K | 159.0K | 192.0K | 255.0K | 712.0K |
| EBITDA | -24.9M | -17.5M | -40.8M | -77.1M | -30.1M | -24.7M | -16.0M | -22.4M | -37.8M | -39.1M |
| Interest expense | 235.0K | 50.0K | 53.0K | 114.0K | 125.0K | 495.0K | 1.41M | 1.86M | 2.52M | 4.58M |
| Income before tax | -1.79M | -20.3M | -40.6M | -77.6M | -32.6M | -27.5M | -20.5M | -18.4M | -39.5M | -55.2M |
| Income tax | 3.69M | -85.9K | -1.37M | -9.99M | -2.29M | 2.39M | -2.93M | 1.99M | 1.20M | 4.67M |
| Net income | -5.49M | -20.3M | -39.2M | -67.6M | -30.3M | -27.5M | -20.5M | -18.4M | -39.5M | -55.2M |
| Earnings per share, basic | -104.35 | -4,712.26 | -125.71 | -685.51 | -2,691.67 | -14,230.63 | -23,759.69 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.78M | 4.32M | 6.17M | 22.3M | 16.9M | 22.6M | 11.2M | 1.81M | 5.59M | 38.7M |
| Short-term investments | 0 | 14.0M | ||||||||
| Current assets | 2.57M | 5.38M | 7.38M | 23.5M | 18.1M | 23.9M | 25.7M | 2.24M | 7.19M | 40.8M |
| Property, plant and equipment | 3.39M | 1.84M | 798.0K | 802.0K | 885.0K | 1.05M | 1.04M | |||
| Goodwill | 0 | 3.06M | 15.7M | 15.7M | 15.7M | 15.7M | ||||
| Total assets | 27.9M | 32.4M | 38.0M | 74.8M | 112.9M | 119.0M | 119.4M | 3.35M | 9.70M | 44.4M |
| Accounts payable | 1.88M | 809.0K | 249.0K | 693.0K | 1.16M | 1.71M | 3.42M | 3.05M | 1.81M | 3.26M |
| Current liabilities | 5.72M | 4.00M | 2.46M | 4.92M | 6.13M | 7.82M | 20.6M | 11.8M | 13.4M | 11.1M |
| Long-term debt | 2.42M | 4.61M | 15.0M | 15.0M | 25.0M | 25.0M | ||||
| Total debt | 1.82M | 16.8M | 2.28M | 2.89M | 3.78M | 20.5M | 23.0M | 15.0M | 25.0M | 25.2M |
| Total liabilities | 17.9M | 29.0M | 27.9M | 32.9M | 43.3M | 44.0M | 51.3M | 27.3M | 38.5M | 36.1M |
| Shareholders' equity | 10.00M | 3.39M | 10.0M | 41.9M | 69.6M | 74.9M | 68.1M | -23.9M | -28.8M | 8.27M |
| Shares outstanding | 52.6K | 4.31K | 700 | 550 | 348 | 218.6K | 30.0K | 6.85K | 2.77K | 2.32K |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.4M | -13.4M | -19.5M | -23.7M | -25.3M | -24.7M | -15.8M | -21.0M | -33.6M | -33.5M |
| Capital spending | -12.0K | -15.0K | -13.0K | -279.0K | -291.0K | -191.0K | -9.00K | -24.0K | -281.0K | -458.0K |
| Free cash flow | -15.4M | -13.5M | -19.5M | -23.9M | -25.6M | -24.9M | -15.8M | -21.1M | -33.9M | -34.0M |
| Cash from investing | -12.0K | -15.0K | 197.0K | -279.0K | -291.0K | 13.8M | -13.7M | -24.0K | -254.0K | -188.0K |
| Cash from financing | 12.7M | 11.6M | 3.08M | 29.4M | 20.0M | 21.8M | 38.7M | 17.3M | 709.0K | 27.7M |
| Dividends paid | -657.0K | 0 | -151 | |||||||
| Share buybacks | -1.88M | 0 | 20.4M | -151 | 32.9M | 1.04M | 709.0K | 32.8M | ||
| Change in cash | -2.68M | -1.86M | -16.2M | 5.42M | -5.65M | 11.4M | 9.32M | -3.77M | -33.1M | -5.99M |
Cap table
Built by 6ix from Windtree Therapeutics, Inc.’s releases
- Common shares
- 33,708,784
- Fully diluted
- 33,708,784
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 33,708,784 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 33,708,784 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bruce Peacock Other companies: Dicerna Pharmaceuticals Inc (Director · Sep 9, 2014 – Jul 18, 2017 · Past); Ocular Therapeutix, Inc. (Director · Jul 24, 2014 – Jun 18, 2021 · Past); IVERIC bio Inc (CFO & CBO · Sep 24, 2013 – Sep 2, 2014 · Past); Ocean Power Technologies, Inc. (Director · Oct 6, 2011 – Oct 4, 2012 · Past); Ligand Pharmaceuticals Incorporated (Director · Dec 23, 2008 – Dec 23, 2008 · Past); NeurogesX Inc (Director · Aug 30, 2007 – May 28, 2009 · Past); Pharmacopeia Inc (Director · May 3, 2007 – Apr 30, 2008 · Past) | Director · Aug 4, 2016 – Feb 3, 2021 · Past |
| Andrew Kucharchuk Other companies: RRE Ventures Acquisition Corp. (Chief Financial Officer · Since at least Apr 29, 2026); Range Capital Acquisition Corp II (Chief Financial Officer · Since at least Oct 2, 2025); CERo Therapeutics Holdings, Inc. (Chief Financial Officer & Director · Since at least Oct 1, 2024); Chain Bridge I (Chief Financial Officer · Apr 1, 2024 – Apr 1, 2024 · Past); Adhera Therapeutics Inc. (Chief Executive Officer, Director · Jul 7, 2020 – Jul 7, 2020 · Past); OncBioMune Pharmaceuticals Inc (Director · May 9, 2018 – Jun 5, 2020 · Past) | Director · Since at least Aug 3, 2025 |
| James Huang Other companies: CASI Pharmaceuticals, Inc. (Director · Since at least Mar 18, 2026); Connect Biopharma Holdings Limited (Founding Partner of Panacea Venture · Since at least Mar 18, 2026); Atara Biotherapeutics, Inc. (Human Capital · Since at least May 16, 2025); Orion Biotech Opportunities Corp (Chief Executive Officer, Director · May 12, 2021 – May 17, 2023 · Past); Alaunos Therapeutics, Inc. (Director · Jul 20, 2020 – Jun 6, 2023 · Past) | Director · Dec 21, 2018 – Feb 22, 2023 · Past |
| John P. Hamill Other companies: Aprea Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023); Trevena, Inc. (VP Fin,Princ Fin&Acct Officer · May 31, 2019 – May 31, 2019 · Past) | SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past |
| Saundra Pelletier Other companies: Aditxt, Inc. (Director · Since at least Jun 5, 2025); Evofem Biosciences, Inc. (Chief Executive Officer, President and Executive Director · Since at least Jan 17, 2018) | Director · Aug 13, 2024 – Aug 13, 2024 · Past |
| Craig Fraser Other companies: Aegerion Pharmaceuticals Inc (Chief Operating Officer · Sep 3, 2012 – Apr 1, 2015 · Past) | President and CEO, Director · Jul 28, 2016 – Oct 8, 2024 · Past |
| Eric Curtis Other companies: Aegerion Pharmaceuticals Inc (President, U.S. Commercial · Aug 26, 2015 – Aug 26, 2015 · Past) | SVP & COO · Mar 9, 2020 – Aug 23, 2023 · Past |
| Jed Latkin Other companies: ProPhase Labs, Inc. (Chief Operating Officer · Jan 1, 2024 – Jan 1, 2024 · Past) | Director · Aug 13, 2024 – Aug 13, 2024 · Past |
| Jamie McAndrew | VP, Controller, & CAO · Aug 24, 2023 – Aug 24, 2023 · Past |
| Mary B Esq Templeton | SVP, Gen Counsel & Corp Sec · Dec 24, 2018 – May 22, 2020 · Past |
Log in to ask 6ix AI your own questions about Windtree Therapeutics, Inc.